Hospital
Mcleod Regional Medical Center of the Pee Dee, INC.
Mcleod Regional Medical Center of the Pee Dee, INC. was paid $90.94M by Medicaid between Jan 2018 and Dec 2024, across 520 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 18% of everything it billed.
33Billing provider infoMCLEOD REGIONAL MEDICAL CENTER OF THE PEE DEE, INC.
FLORENCE, SC 29506
FLORENCE, SC 29506
33aNPI1699756221assigned 11/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$90.94M
24GClaims2,335,676
24DCodes billed520
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#2 of 115
Median peer was paid$2.47M
This provider vs. median37×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ERVIN, SAMUEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 283,133 | $8.06M | |
| 2019 | 317,447 | $9.74M | |
| 2020 | 350,530 | $10.65M | |
| 2021 | 389,157 | $13.38M | |
| 2022 | 367,835 | $15.11M | |
| 2023 | 332,122 | $18.50M | |
| 2024incomplete | 295,452 | $15.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 18% | 150,053 | 102,087 | $16.70M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 10% | 27,684 | 19,038 | $9.14M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6.0% | 19,645 | 17,898 | $5.44M |
| 96367 | 4.6% | 8,513 | 4,413 | $4.22M | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.9% | 13,192 | 7,094 | $3.56M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 50,313 | 13,665 | $2.21M |
| 59025 | Fetal non-stress test | 1.8% | 16,012 | 8,623 | $1.68M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 13,292 | 12,165 | $1.66M |
| A9585 | Injection, gadobutrol, 0.1 ml | 1.8% | 3,193 | 3,028 | $1.65M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.7% | 2,288 | 2,176 | $1.54M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 31,039 | 21,171 | $1.50M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 10,008 | 7,458 | $1.45M |
508 more codes
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1.5% | 2,010 | $1.33M |
| 99283 | Emergency room visit (moderate) | 1.5% | 32,293 | $1.33M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 12,824 | $1.26M |
| 96402 | 1.4% | 1,196 | $1.26M | |
| 80053 | Comprehensive metabolic panel | 1.4% | 71,370 | $1.25M |
| 36416 | 1.3% | 24,741 | $1.20M | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.2% | 22,179 | $1.10M |
| J7050 | Infusion, normal saline solution, 250 cc | 1.2% | 15,804 | $1.08M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 19,299 | $982K |
| 99284 | Emergency room visit (serious) | 1.0% | 47,186 | $912K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,487 | $901K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 59,296 | $900K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,928 | $873K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,637 | $780K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 30,664 | $735K |
| 81002 | <1% | 3,732 | $731K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,561 | $720K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,781 | $672K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,303 | $670K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 19,475 | $641K |
| 77334 | <1% | 1,455 | $635K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 26,129 | $623K |
| 81001 | <1% | 38,780 | $576K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 6,628 | $534K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,167 | $532K |
| 82948 | <1% | 15,644 | $478K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 38,764 | $466K |
| 71250 | <1% | 2,669 | $465K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,519 | $437K |
| 88304 | <1% | 3,531 | $429K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13,875 | $411K |
| 96401 | <1% | 344 | $386K | |
| 77387 | <1% | 4,101 | $381K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,175 | $377K |
| 81003 | <1% | 18,122 | $365K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,496 | $330K |
| 72141 | <1% | 751 | $326K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,022 | $309K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,188 | $307K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,131 | $289K |
| 77336 | <1% | 3,756 | $277K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,327 | $276K |
| 81025 | <1% | 24,671 | $267K | |
| D1351 | Sealant - per tooth | <1% | 278 | $246K |
| 96523 | <1% | 1,940 | $241K | |
| 93971 | <1% | 2,329 | $240K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,719 | $232K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 1,054 | $231K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,187 | $229K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 2,492 | $223K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,172 | $214K |
| 71045 | Radiologic examination, chest; single view | <1% | 35,254 | $207K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 120,389 | $198K |
| 77300 | <1% | 1,011 | $183K | |
| 99285 | Emergency room visit (most serious) | <1% | 33,289 | $175K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,668 | $175K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 824 | $173K |
| G0378 | Hospital observation service, per hour | <1% | 29,362 | $171K |
| 82803 | <1% | 4,834 | $155K | |
| 90378 | <1% | 1,324 | $147K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,615 | $146K |
| 73130 | <1% | 2,085 | $144K | |
| 86850 | <1% | 8,619 | $140K | |
| 96376 | <1% | 14,873 | $139K | |
| V2632 | Posterior chamber intraocular lens | <1% | 588 | $138K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,887 | $137K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 596 | $137K |
| 94060 | <1% | 561 | $136K | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 4,995 | $132K |
| 77386 | <1% | 2,568 | $131K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 467 | $128K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,072 | $127K |
| 87070 | <1% | 2,494 | $125K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,938 | $124K |
| 73030 | <1% | 2,758 | $121K | |
| 73610 | <1% | 1,993 | $119K | |
| 72100 | <1% | 3,396 | $119K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 468 | $113K |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 1,619 | $112K |
| D2330 | <1% | 272 | $110K | |
| 73564 | <1% | 2,830 | $108K | |
| 74018 | <1% | 2,839 | $108K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,100 | $105K |
| 73630 | <1% | 2,521 | $104K | |
| 93970 | <1% | 1,118 | $104K | |
| J2704 | Injection, propofol, 10 mg | <1% | 29,993 | $102K |
| 77295 | <1% | 80 | $101K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,221 | $99K |
| 94010 | <1% | 370 | $94K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 264 | $90K |
| 97161 | <1% | 6,462 | $90K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,597 | $88K |
| 93922 | <1% | 441 | $87K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,580 | $85K |
| 85014 | <1% | 5,187 | $81K | |
| 96368 | <1% | 1,532 | $74K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 1,062 | $74K |
| 87077 | <1% | 3,736 | $73K | |
| 87205 | <1% | 3,887 | $72K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44,628 | $70K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,936 | $69K |
| 84439 | <1% | 5,045 | $65K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 613 | $63K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,969 | $62K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,990 | $60K |
| 36600 | <1% | 3,441 | $58K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,479 | $57K |
| 71271 | <1% | 391 | $55K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,413 | $55K |
| 76770 | <1% | 785 | $55K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 543 | $53K |
| 73110 | <1% | 925 | $53K | |
| 76642 | <1% | 1,266 | $52K | |
| 72040 | <1% | 1,011 | $52K | |
| 76536 | <1% | 664 | $52K | |
| 85610 | <1% | 28,915 | $51K | |
| 70486 | <1% | 1,675 | $51K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12,094 | $51K |
| 97602 | <1% | 1,603 | $50K | |
| A6261 | Wound filler, gel/paste, per fluid ounce, not otherwise specified | <1% | 514 | $50K |
| 77412 | <1% | 5,447 | $49K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,598 | $48K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,873 | $48K |
| 77062 | <1% | 252 | $46K | |
| 29581 | <1% | 7,888 | $46K | |
| 82565 | <1% | 3,314 | $44K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 490 | $44K |
| 73502 | <1% | 1,776 | $43K | |
| 88307 | <1% | 1,540 | $42K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,904 | $41K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,487 | $39K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,969 | $39K |
| 85027 | <1% | 16,136 | $38K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15,173 | $37K |
| 73090 | <1% | 594 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,690 | $36K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 49 | $36K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 31,172 | $35K |
| J3490 | Unclassified drugs | <1% | 10,669 | $34K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 1,901 | $33K |
| 74022 | <1% | 1,410 | $33K | |
| 92523 | <1% | 395 | $32K | |
| 76830 | Ultrasound, transvaginal | <1% | 670 | $31K |
| 84112 | <1% | 95 | $31K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 366 | $30K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,395 | $30K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,042 | $27K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 732 | $27K |
| 97116 | <1% | 1,780 | $26K | |
| 97165 | <1% | 1,376 | $26K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 19,090 | $25K |
| 77080 | <1% | 233 | $25K | |
| 83735 | <1% | 40,761 | $25K | |
| 73590 | <1% | 1,053 | $24K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 6,042 | $23K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 7,445 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,114 | $22K |
| 93880 | <1% | 275 | $22K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,023 | $22K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 440 | $22K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,387 | $22K |
| C1769 | Guide wire | <1% | 6,403 | $20K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 191 | $19K |
| 97533 | <1% | 3,048 | $19K | |
| 76641 | <1% | 234 | $19K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,952 | $19K |
| 87400 | <1% | 358 | $18K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 366 | $17K |
| 72070 | <1% | 401 | $17K | |
| 76775 | <1% | 290 | $17K | |
| 97162 | <1% | 920 | $17K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,770 | $16K |
| 88302 | <1% | 231 | $16K | |
| 73560 | <1% | 976 | $16K | |
| 77290 | <1% | 28 | $16K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,766 | $16K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,182 | $16K |
| 73080 | <1% | 212 | $15K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,878 | $15K |
| 93017 | <1% | 1,685 | $15K | |
| 95811 | <1% | 52 | $14K | |
| 85730 | <1% | 27,095 | $14K | |
| 97113 | <1% | 551 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,347 | $14K |
| 76801 | <1% | 829 | $14K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 132 | $13K |
| 49083 | <1% | 66 | $13K | |
| 72131 | <1% | 229 | $13K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,054 | $13K |
| 94762 | <1% | 723 | $13K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 174 | $12K |
| 86900 | <1% | 10,965 | $12K | |
| 10060 | <1% | 81 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 555 | $11K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 23,379 | $11K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,446 | $11K |
| 80076 | <1% | 13,812 | $10K | |
| 83690 | <1% | 23,265 | $10K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 4,621 | $10K |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 97 | $10K |
| 76937 | <1% | 1,040 | $10K | |
| 62323 | <1% | 131 | $9K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,071 | $9K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,969 | $9K |
| 82570 | <1% | 2,062 | $9K | |
| 77066 | Tomosynthesis, mammo | <1% | 874 | $9K |
| 84702 | <1% | 5,128 | $8K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 978 | $8K |
| 72170 | <1% | 570 | $7K | |
| 88342 | <1% | 2,706 | $7K | |
| 86140 | <1% | 4,358 | $7K | |
| 89051 | <1% | 118 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,904 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 145 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,950 | $7K |
| 87807 | <1% | 1,817 | $7K | |
| 97014 | <1% | 53 | $7K | |
| 97164 | <1% | 577 | $7K | |
| 36902 | <1% | 1,136 | $7K | |
| 71101 | <1% | 72 | $7K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 919 | $6K |
| 77280 | <1% | 88 | $6K | |
| 87186 | <1% | 4,190 | $6K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,885 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 15,138 | $6K |
| 92609 | <1% | 282 | $6K | |
| 87640 | <1% | 1,736 | $6K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 1,058 | $6K |
| 82607 | <1% | 2,178 | $5K | |
| 80061 | Lipid panel | <1% | 6,186 | $5K |
| 76870 | <1% | 55 | $5K | |
| 82330 | <1% | 959 | $5K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 755 | $5K |
| 73552 | <1% | 304 | $5K | |
| 95951 | <1% | 15 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,316 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,762 | $5K |
| 12001 | <1% | 43 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,342 | $5K |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 88 | $5K |
| 90686 | <1% | 1,238 | $5K | |
| 94644 | <1% | 4,302 | $5K | |
| 86592 | <1% | 2,072 | $5K | |
| 93458 | <1% | 120 | $5K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 25 | $5K |
| 83615 | <1% | 1,932 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,373 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 375 | $5K |
| 85018 | <1% | 4,940 | $5K | |
| 77072 | <1% | 126 | $5K | |
| 88112 | <1% | 97 | $4K | |
| 72158 | <1% | 40 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,733 | $4K |
| 43235 | <1% | 153 | $4K | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 217 | $4K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,831 | $4K |
| 88173 | <1% | 62 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,708 | $4K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 408 | $4K |
| 87081 | <1% | 35 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 280 | $4K |
| 78227 | <1% | 13 | $4K | |
| 82728 | <1% | 4,003 | $4K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,373 | $4K |
| 94760 | <1% | 883 | $4K | |
| 96377 | <1% | 155 | $4K | |
| 73060 | <1% | 121 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,017 | $4K |
| 90670 | <1% | 539 | $4K | |
| 95816 | <1% | 41 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,412 | $4K |
| 77001 | <1% | 807 | $3K | |
| 73562 | <1% | 76 | $3K | |
| 77061 | <1% | 29 | $3K | |
| 93798 | <1% | 60 | $3K | |
| 83550 | <1% | 3,932 | $3K | |
| 87430 | <1% | 657 | $3K | |
| 86901 | <1% | 10,978 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,236 | $3K |
| 86703 | <1% | 1,518 | $3K | |
| 84156 | <1% | 1,235 | $3K | |
| 85046 | <1% | 3,480 | $3K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 31 | $3K |
| 72197 | <1% | 42 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,645 | $3K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 200 | $3K |
| 96411 | <1% | 1,533 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,382 | $3K |
| 97166 | <1% | 57 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,401 | $2K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 183 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,779 | $2K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 510 | $2K |
| 99201 | <1% | 27 | $2K | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 28 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,337 | $2K |
| 93454 | <1% | 15 | $2K | |
| 84132 | <1% | 2,208 | $2K | |
| 74220 | <1% | 50 | $2K | |
| 85379 | <1% | 4,549 | $2K | |
| 73700 | <1% | 15 | $2K | |
| 74221 | <1% | 13 | $2K | |
| 87040 | <1% | 8,437 | $2K | |
| 83880 | <1% | 10,590 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 3,000 | $2K |
| 84484 | <1% | 30,390 | $2K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 743 | $2K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 413 | $2K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 1,047 | $2K |
| 36581 | <1% | 16 | $1K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 44 | $1K |
| 82375 | <1% | 12 | $1K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 646 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 125 | $1K |
| 82550 | <1% | 1,875 | $1K | |
| 74174 | <1% | 41 | $1K | |
| A9270 | Non-covered item or service | <1% | 11,184 | $1K |
| 87210 | <1% | 1,796 | $1K | |
| 70496 | <1% | 76 | $1K | |
| 83540 | <1% | 3,960 | $1K | |
| 84100 | <1% | 4,509 | $985.32 | |
| 70491 | <1% | 229 | $970.52 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 799 | $861.28 |
| 84145 | <1% | 2,668 | $840.82 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 762 | $815.78 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 510 | $815.78 |
| 96417 | <1% | 3,910 | $804.25 | |
| 82947 | <1% | 1,100 | $786.39 | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 79 | $778.33 |
| 90715 | <1% | 1,974 | $746.22 | |
| 97035 | <1% | 23 | $740.29 | |
| 93976 | <1% | 25 | $740.18 | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 222 | $713.91 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,681 | $711.53 |
| 83605 | <1% | 7,990 | $678.99 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,072 | $661.42 |
| 80143 | <1% | 2,557 | $656.63 | |
| 78306 | <1% | 12 | $643.31 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 20 | $623.14 |
| 96415 | <1% | 2,789 | $622.17 | |
| 74230 | <1% | 13 | $575.84 | |
| 94729 | <1% | 1,051 | $546.96 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 110 | $516.59 |
| 87147 | <1% | 563 | $496.10 | |
| 82043 | <1% | 1,159 | $489.04 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 2,169 | $479.99 |
| 75574 | <1% | 81 | $473.68 | |
| Q3014 | Telehealth originating site facility fee | <1% | 682 | $445.95 |
| 86738 | <1% | 334 | $429.79 | |
| 94726 | <1% | 910 | $425.78 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 159 | $407.89 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 408 | $358.74 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 720 | $355.81 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 859 | $335.93 |
| 36430 | <1% | 1,994 | $326.28 | |
| 84550 | <1% | 1,575 | $320.90 | |
| 43249 | <1% | 90 | $261.92 | |
| 85652 | <1% | 4,790 | $235.37 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 31 | $201.91 |
| 82784 | <1% | 691 | $201.06 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 347 | $199.01 |
| 87140 | <1% | 594 | $191.48 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 27 | $185.14 |
| 88341 | <1% | 232 | $164.36 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 561 | $146.18 |
| 90677 | <1% | 95 | $145.99 | |
| 83655 | <1% | 13 | $145.95 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,435 | $134.88 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 13 | $132.76 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 107 | $116.23 |
| 82077 | <1% | 4,126 | $112.86 | |
| 70360 | <1% | 12 | $112.06 | |
| 82247 | <1% | 168 | $110.66 | |
| 82378 | <1% | 957 | $108.63 | |
| 86038 | <1% | 151 | $103.75 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 19 | $96.99 |
| 80329 | <1% | 195 | $88.00 | |
| 87641 | <1% | 1,963 | $71.44 | |
| 74178 | <1% | 29 | $66.89 | |
| 99152 | <1% | 1,472 | $59.92 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 79 | $55.22 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,554 | $50.58 |
| 80164 | <1% | 275 | $45.95 | |
| 73070 | <1% | 17 | $44.87 | |
| 87340 | <1% | 1,601 | $40.64 | |
| 90698 | <1% | 130 | $39.82 | |
| 80179 | <1% | 2,510 | $38.59 | |
| 90461 | <1% | 719 | $38.22 | |
| 90680 | <1% | 16 | $35.74 | |
| 75635 | <1% | 49 | $28.52 | |
| 86923 | <1% | 529 | $21.60 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 302 | $15.45 |
| 82746 | <1% | 1,274 | $12.76 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 326 | $10.84 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,308 | $10.46 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,751 | $8.44 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 343 | $7.86 |
| 84295 | <1% | 734 | $7.53 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 378 | $7.29 |
| 80320 | <1% | 1,070 | $7.17 | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 0% | 1,511 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 286 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 446 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 1,093 | $0.00 |
| 84703 | 0% | 400 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 590 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 416 | $0.00 |
| 94660 | 0% | 155 | $0.00 | |
| 87449 | 0% | 183 | $0.00 | |
| A6550 | Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories | 0% | 59 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 823 | $0.00 |
| D3310 | 0% | 111 | $0.00 | |
| 86803 | 0% | 258 | $0.00 | |
| 84153 | 0% | 164 | $0.00 | |
| 87088 | 0% | 48 | $0.00 | |
| 77417 | 0% | 25 | $0.00 | |
| 82985 | 0% | 226 | $0.00 | |
| 96409 | 0% | 23 | $0.00 | |
| 83521 | 0% | 417 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 216 | $0.00 |
| J2505 | Injection, pegfilgrastim, 6 mg | 0% | 241 | $0.00 |
| 64721 | 0% | 67 | $0.00 | |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | 0% | 172 | $0.00 |
| 90634 | 0% | 17 | $0.00 | |
| C1768 | Graft, vascular | 0% | 45 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 14 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 54 | $0.00 |
| D1208 | Topical application of fluoride, excluding varnish | 0% | 73 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 376 | $0.00 |
| 72020 | 0% | 39 | $0.00 | |
| 86920 | 0% | 63 | $0.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 208 | $0.00 |
| 70498 | 0% | 77 | $0.00 | |
| 74420 | 0% | 12 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 96 | $0.00 |
| 85660 | 0% | 28 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 56 | $0.00 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 23 | $0.00 |
| 83883 | 0% | 26 | $0.00 | |
| 19083 | 0% | 13 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 40 | $0.00 |
| J2404 | Injection, nicardipine, 0.1 mg | 0% | 16 | $0.00 |
| 12002 | 0% | 15 | $0.00 | |
| 90656 | 0% | 12 | $0.00 | |
| 90651 | 0% | 15 | $0.00 | |
| C9463 | Injection, aprepitant, 1 mg | 0% | 28 | $0.00 |
| 80050 | General health panel | 0% | 30 | $0.00 |
| 90744 | 0% | 31 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 20 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 18 | $0.00 |
| J9035 | Injection, bevacizumab, 10 mg | 0% | 28 | $0.00 |
| 84155 | 0% | 331 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 2,412 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 92 | $0.00 |
| 96416 | 0% | 433 | $0.00 | |
| 36905 | 0% | 207 | $0.00 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 0% | 57 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 926 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 267 | $0.00 |
| 82248 | 0% | 263 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 157 | $0.00 |
| 86334 | 0% | 261 | $0.00 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 736 | $0.00 |
| 83970 | 0% | 28 | $0.00 | |
| 87075 | 0% | 89 | $0.00 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 0% | 784 | $0.00 |
| 84165 | 0% | 397 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 346 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 87 | $0.00 |
| C1729 | Catheter, drainage | 0% | 15 | $0.00 |
| 84520 | 0% | 41 | $0.00 | |
| 36830 | 0% | 38 | $0.00 | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 78 | $0.00 |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 0% | 12 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 152 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 839 | $0.00 |
| 77012 | 0% | 12 | $0.00 | |
| 27447 | 0% | 24 | $0.00 | |
| 94645 | 0% | 41 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 29 | $0.00 |
| 82140 | 0% | 78 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 91 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 168 | $0.00 |
| C9088 | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg | 0% | 13 | $0.00 |
| 36558 | 0% | 14 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 15 | $0.00 |
| 85347 | 0% | 20 | $0.00 | |
| 90633 | 0% | 15 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 31 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 16 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 50 | $0.00 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 0% | 57 | $0.00 |
| 97168 | 0% | 70 | $0.00 | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | 0% | 14 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 36 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 33 | $0.00 |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 13 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 24 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 15 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 15 | $0.00 |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 0% | 27 | $0.00 |
| D2932 | 0% | 13 | $0.00 | |
| 77301 | 0% | 15 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 31 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 38 | $0.00 |
| 92611 | 0% | 13 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 23 | $0.00 |
| 77338 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialERVIN, SAMUEL (SR VP AND CFO)
Parent organizationMCLEOD HEALTH
| Provider | Location | Paid |
|---|---|---|
| Mcleod Loris Seacoast Hospital | Loris, SC | $24.76M |
| Mcleod Medical Center-Dillon | Dillon, SC | $13.63M |
| Mcleod Regional Medical Center of the Pee Dee, INC | Florence, SC | $12.62M |
| Mcleod Health Clarendon | Manning, SC | $10.05M |
| Mcleod Health Cheraw | Cheraw, SC | $6.77M |
| Mcleod Regional Medical Center of the Pee Dee, INC. | Florence, SC | $5.72M |
| Mcleod Regional Medical Center of the Pee Dee, INC | Florence, SC | $2.73M |
| Mcleod Health Clarendon | Manning, SC | $1.43M |
| Mcleod Health Cheraw | Cheraw, SC | $1.37M |
| Mcleod Regional Medical Center of the Pee Dee, INC. | Florence, SC | $1.32M |
| Mcleod Health Cheraw | Bennettsville, SC | $912K |
| Mcleod Health Cheraw | Darlington, SC | $653K |
| Mcleod Regional Medical Center of the Pee Dee, INC. | Darlington, SC | $582K |
| Mcleod Health Clarendon | Kingstree, SC | $440K |
| Mcleod Health Clarendon | Johnsonville, SC | $438K |
| Mcleod Health Clarendon | Timmonsville, SC | $382K |
| Mcleod Health Clarendon | Manning, SC | $334K |
| Mcleod Health Cheraw | Mullins, SC | $283K |
| Mcleod Health Clarendon | Manning, SC | $273K |
| Mcleod Loris Seacoast Hospital | Loris, SC | $247K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.